Literature DB >> 35705773

Association of TP53 gene polymorphisms with the risk of acute lymphoblastic leukemia in Moroccan children.

Hanaa Skhoun1,2, Mohammed Khattab3, Aziza Belkhayat4, Zahra Takki Chebihi4, Youssef Bakri2, Nadia Dakka2, Jamila El Baghdadi5.   

Abstract

BACKGROUND: TP53 gene plays a pivotal role in maintaining genetic stability and prevention of malignancies. Alterations of this gene are implicated in more than half of human cancers. To the best of our knowledge, this study is the first to explore TP53 polymorphisms in Moroccan childhood acute lymphoblastic leukemia (ALL). METHODS AND
RESULTS: DNA samples of 45 ALL children were obtained from peripheral blood. A total of 333 healthy Moroccans were used as controls. Polymerase chain reaction and Sanger sequencing were performed to analyze TP53 hotspot exons in cases. We identified a significant protective effect of the TP53-Arg variant at rs1042522 [OR 0.4593 (0.249-0.8472), p = 0.0127] and the Pro/Arg genotype [OR 0.0350 (0.0047-0.2583), p = 0.0010]. Additionally, we found a novel association between the C-allele of Arg213Arg 1800372 [OR 2.7736 (1.3821-5.5664), p = 0.0041] and the risk of childhood ALL. Importantly, TC/CC genotypes of this polymorphism were revealed to enhance the risk of ALL among females [OR 9.0 (3.1555-25.6693), p < 0.0001]. Arg213Arg was also noticed to be associated with the hemoglobin count of patients at diagnosis by linear regression (p = 0.0318). The analysis of penetrance showed a significant association of the CG/GG genotypes at rs1042522 and TC/CC genotypes at rs1800372 to childhood ALL via dominant model [OR 0.2090 (0.09074-0.4814), p = 0.0002 and OR 3.4205 (1.6084-7.2742), p = 0.0014 for rs1042522 and rs1800372 respectively]. No association was found between TP53 polymorphisms and patients survival.
CONCLUSION: Altogether, our findings indicated that TP53 polymorphisms are significantly involved in the genetic susceptibility to childhood ALL in Morocco.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Moroccan children; Polymorphisms; TP53

Mesh:

Substances:

Year:  2022        PMID: 35705773     DOI: 10.1007/s11033-022-07643-3

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.742


  47 in total

Review 1.  Biology of childhood acute lymphoblastic leukemia.

Authors:  Deepa Bhojwani; Jun J Yang; Ching-Hon Pui
Journal:  Pediatr Clin North Am       Date:  2015-02       Impact factor: 3.278

Review 2.  Genomics in acute lymphoblastic leukaemia: insights and treatment implications.

Authors:  Kathryn G Roberts; Charles G Mullighan
Journal:  Nat Rev Clin Oncol       Date:  2015-03-17       Impact factor: 66.675

Review 3.  TP53 Mutations in Hypodiploid Acute Lymphoblastic Leukemia.

Authors:  Evan Q Comeaux; Charles G Mullighan
Journal:  Cold Spring Harb Perspect Med       Date:  2017-03-01       Impact factor: 6.915

Review 4.  Genetic Basis of Acute Lymphoblastic Leukemia.

Authors:  Ilaria Iacobucci; Charles G Mullighan
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

Review 5.  Acute lymphoblastic leukaemia.

Authors:  Hiroto Inaba; Mel Greaves; Charles G Mullighan
Journal:  Lancet       Date:  2013-03-22       Impact factor: 79.321

6.  30 years and a long way into p53 research.

Authors:  Pierre Hainaut; Klas G Wiman
Journal:  Lancet Oncol       Date:  2009-09       Impact factor: 41.316

Review 7.  p53: guardian of the genome and policeman of the oncogenes.

Authors:  Alejo Efeyan; Manuel Serrano
Journal:  Cell Cycle       Date:  2007-05-28       Impact factor: 4.534

Review 8.  Gain of function of p53 cancer mutants in disrupting critical DNA damage response pathways.

Authors:  Hoseok Song; Yang Xu
Journal:  Cell Cycle       Date:  2007-05-22       Impact factor: 4.534

Review 9.  Mechanisms of transcriptional regulation by p53.

Authors:  Kelly D Sullivan; Matthew D Galbraith; Zdenek Andrysik; Joaquin M Espinosa
Journal:  Cell Death Differ       Date:  2017-11-10       Impact factor: 15.828

10.  The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes.

Authors:  K L McGraw; L M Zhang; D E Rollison; A A Basiorka; W Fulp; B Rawal; A Jerez; D L Billingsley; H-Y Lin; S E Kurtin; S Yoder; Y Zhang; K Guinta; M Mallo; F Solé; M J Calasanz; J Cervera; E Such; T González; T J Nevill; T Haferlach; A E Smith; A Kulasekararaj; G Mufti; A Karsan; J P Maciejewski; L Sokol; P K Epling-Burnette; S Wei; A F List
Journal:  Blood Cancer J       Date:  2015-03-13       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.